Direct and indirect costs of influenza-like illness treated with and without oseltamivir in 15 European countries: a descriptive analysis alongside the randomised controlled ALIC4E trial

<p><strong>Background and Objective</strong></p> Influenza-like illness (ILI) leads to a substantial disease burden every winter in Europe; however, oseltamivir is not frequently prescribed to ILI patients in the primary-care setting. An open-label, multi-country, multi-seaso...

Full description

Bibliographic Details
Main Authors:	Li, X, Bilcke, J, van der Velden, AW, Bongard, E, Bruyndonckx, R, Sundvall, P-D, Harbin, NJ, Coenen, S, Francis, N, Bruno, P, Garcia-Sangenis, A, Glinz, D, Kosiek, K, Mikó-Pauer, R, Radzeviciene Jurgute, R, Seifert, B, Tsakountakis, N, Aabenhus, R, Butler, CC, Beutels, P
Format:	Journal article
Language:	English
Published:	Springer 2021

Direct and indirect costs of influenza-like illness treated with and without oseltamivir in 15 European countries: a descriptive analysis alongside the randomised controlled ALIC4E trial

Similar Items